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            Amendments from Version 1
We have taken into account the considered and constructive 
analysis of our manuscript by the two reviewers. We have 
addressed individual comments and submit this revised version 2.
We have highlighted that we identified only external ophthalmic 
signs in our cohort, and have recognised a possible trial effect 
of multiple lumbar punctures on apparently low incidence of 
neurological signs. We also acknowledge the added limitation in 




Cryptococcal meningitis is the commonest neurological 
complication in patients with advanced HIV, accounting for 
15% of AIDS-related deaths1. Visual disturbance is a frequent 
presenting symptom including reduced visual acuity, blurred 
vision, diplopia and photophobia. In a South African study of 
patients with HIV-associated meningitis due to Cryptococcus 
neoformans, 47% (40/86) had decreased visual acuity2. Visual loss 
may occur secondary to raised intracranial pressure or be due to 
direct fungal invasion of the optic nerve, optic chiasm or optic 
tracts3,4.
Papilloedema is reported to be the most common ophthalmic 
sign in cryptococcal meningitis, prevalence ranging between 
33% and 48%5–7 in case series. Other ophthalmic signs described 
in case reports include: retinal haemorrhages8, multi-focal 
choroiditis9, optic atrophy10, vascular tortuosity11, exudative 
retinal detachment12 and intraocular cryptococcoma13. Ophthalmic 
signs in patients with cryptococcal meningitis may be indicative 
of neurological dysfunction including cranial nerve palsies14,15 
or may reflect concurrent systemic disease in patients with 
advanced HIV.
We conducted an observational study of HIV-infected adults 
with acute cryptococcal meningitis to describe the range and 
relative incidence of external ophthalmic signs.
Methods
The study was nested within the Adjunctive Sertraline for 
the Treatment of HIV-Associated Cryptococcal Meningitis 
(ASTRO-CM) trial (ClinicalTrials.gov number: NCT01802385). 
ASTRO-CM was a phase III randomized controlled trial to 
evaluate whether adjunctive sertraline improved survival when 
added to standard amphotericin-based therapy for cryptococcal 
meningitis. Primary outcome was 18-week survival. We enrolled 
HIV-infected adults (≥18 years) presenting with cryptococcal 
meningitis (diagnosed by cerebrospinal fluid (CSF) cryptococ-
cal antigen positivity) to Mulago National Referral Hospital, 
Kampala or Mbarara Regional Referral Hospital, Uganda 
between August 2013 and May 2017. Patients were required 
to be willing to undergo protocol-specified lumbar punctures; 
and were excluded if they had already received 3 doses of 
amphotericin B, if they had jaundice or known liver cirrhosis, 
or were pregnant or currently breastfeeding. Patients were 
hospitalized for 2 weeks and thereafter seen every 2 weeks as 
outpatients through 18 weeks.
Standard clinical and examination data were collected as part 
of the randomized controlled trial. We screened participants for 
visual disturbance and external ophthalmic signs at baseline 
and at each follow-up appointment, via clinical history and 
examination with a simple light source such as a pen torch. 
Incident ophthalmic symptoms and signs were ascribed by 
the attending study physician when first observed based on 
standard clinical case definitions (abnormal signs which persisted 
were not re-recorded at each follow-up visit).
Analysis was primarily descriptive and was performed using 
Microsoft Excel® 2016. We summarized the observational data 
as proportions or medians with inter-quartile ranges (IQR). For 
the descriptive analysis, we categorized ophthalmic abnormali-
ties into three groups: (i) neurological signs (ii) localized ocular 
pathology (iii) evidence of concurrent systemic disease.
Results
We screened 696 adults with HIV-associated cryptococcal 
meningitis for visual disturbance and external ophthalmic signs. 
87.2% of patients presented as a first episode of cryptococcal 
meningitis, with the remaining 12.8% having had a previous 
episode. The mean age was 36 years (range 18–70 years), and 
60% (421/696) were men. All patients had advanced HIV with a 
median CD4 count 16 cells/mm3 (IQR 6 - 49) and mean hemo-
globin of 11.6 g/dL. Diagnostic lumbar punctures were undertaken 
on all patients and revealed a median opening pressure of 
270 mmHg (IQR 180 – 410), and a median CSF fungal burden of 
38,000 cfu/ml (IQR 790 – 236,750).
Overall, 184 participants (26.4%) displayed external ophthalmic 
signs or symptoms during the study period, with a total of 227 
abnormal findings documented (Table 1). Thirty-eight participants 
(5.5%) displayed more than one sign or symptom, either concur-
rently or sequentially (median 2; range 2–4). Ophthalmic signs were 
diagnosed throughout the study period: at initial assessment 
(n=80; 11.5%); during inpatient consultation (n=92; 13.2%); and 
during outpatient consultation (n=65; 9.3%).
Ninety participants (12.9%) displayed ophthalmic manifesta-
tions of systemic disease, with conjunctival pallor the most 
frequently reported sign (n=48; 6.9%). Sixty-three patients 
(9.1%) had ocular signs or symptoms, the most common being 
‘reported visual disturbance’ (n=32; 4.6%) – a disparate category 
which grouped all subjective visual deficit in the absence of other 
objective signs. Conjunctivitis was also frequently noted on 
examination (n=22; 3.2%). Cranial nerve palsies (III, IV, VI 
or VII) occurred in 49 patients (7.0%), with the most common 
being a unilateral VI palsy (n=17; 2.4%). Other neurological 
symptoms were less commonly seen and included conjugate 
gaze palsy (n=6), nystagmus (n=2) and bilateral miosis (n=1).
Conclusions
Ophthalmic signs and symptoms were present in more 
than a quarter of our cohort of Ugandan adults with HIV- 
associated cryptococcal meningitis, consistent with previous 
literature reporting ophthalmic findings to be common in this 
population1,2,8,16,17, although heterogeneity in study design should 
is noted. The complexity of this patient group is demonstrated 
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Table 1. Frequency of external ophthalmic signs and symptoms in Ugandan adults 
with HIV-associated cryptococcal meningitis. I) Initial assessment (baseline); II) During 
inpatient stay; III) During subsequent outpatient consultations. Results displayed as 
raw data and as a percentage of the total study population (N=696). aReported Visual 
Disturbance represents the only patient-reported variable; otherwise signs are reported as 









Any Ophthalmic Sign or Symptom 80 (11.5) 92 (13.2) 65 (9.3) 184 (26.4)
       Systemic
              Pallor/Anaemia 12 (1.7) 21 (3.0) 15 (2.2) 48 (6.9)
              Jaundice/Icterus 2 (0.3) 16 (2.3) 2 (0.3) 20 (2.9)
              Dehydration/Sunken Eyes 1 (0.1) 3 (0.4) 3 (0.4) 7 (1.0)
              Periorbital Oedema 4 (0.6) 3 (0.4) 0 (0.0) 7 (1.0)
              Abnormal Periorbital Skin 4 (0.6) 4 (0.6) 0 (0.0) 8 (1.1)
              Total 23 (3.3) 47 (6.8) 20 (2.9) 90 (12.9)
       Ocular
              Reported Visual Disturbancea 14 (2.0) 10 (1.4) 8 (1.1) 32 (4.6)
              Conjunctivitis/Redness 6 (0.9) 3 (0.4) 13 (1.9) 22 (3.2)
              Conjunctival Haemorrhage 1 (0.1) 3 (0.4) 1 (0.1) 5 (0.7)
              Exophthalmos/Proptosis 3 (0.4) 0 (0.0) 0 (0.0) 3 (0.4)
              Cataract 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.1)
              Total 24 (3.4) 17 (2.4) 22 (3.2) 63 (9.1)
       Neurological
              Abnormal Pupillary Light Reflex
                     Unilateral 5 (0.7) 2 (0.3) 2 (0.3) 9 (1.3)
                     Bilateral 2 (0.3) 5 (0.7) 2 (0.3) 9 (1.3)
              III Palsy
                     Unilateral 5 (0.7) 2 (0.3) 2 (0.3) 9 (1.3)
                     Bilateral 0 (0.0) 0 (0.0) 1 (0.1) 1 (0.1)
              IV Palsy
                     Unilateral 1 (0.1) 0 (0.0) 2 (0.3) 3 (0.4)
                     Bilateral 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
              VI Palsy
                     Unilateral 12 (1.7) 4 (0.6) 1 (0.1) 17 (2.4)
                     Bilateral 1 (0.1) 2 (0.3) 1 (0.1) 4 (0.6)
              VII Palsy
                     Unilateral 0 (0.0) 2 (0.3) 1 (0.1) 3 (0.4)
                     Bilateral 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
              Squint/CN Palsy NOSb 7 (1.0) 2 (0.3) 3 (0.4) 12 (1.7)
              Conjugate Gaze Palsy
                     Lateral 1 (0.1) 2 (0.3) 2 (0.3) 5 (0.7)
                     Vertical 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.1)
              Nystagmus
                     Horizontal 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.1)
                     Vertical 0 (0.0) 1 (0.1) 0 (0.0) 1 (0.1)
              Bilateral Miosis 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.1)
              Total 36 (5.2) 23 (3.3) 17 (2.4) 76 (10.9)
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in the breadth of signs present, both those indicative of systemic 
disease and those representing concurrent ocular and neurological 
pathology.
Abnormal examination findings were diagnosed throughout the 
study period and were equally incident across initial examina-
tion, inpatient and outpatient assessment; it is therefore essential 
that a high clinical vigilance is maintained at every stage of 
management in these patients.
All reported signs and symptoms were elicited through basic 
clinical history and examination, requiring only a simple light 
source such as a pen torch. This demonstrates the potential for 
identifying a large spectrum of systemic, ocular and 
neurological disease even in a low-resource setting. The absence 
of equipment such as Snellen charts in our study may partly 
explain the low incidence of reported visual disturbance in 
our population (4.6%), when compared to previously published 
case series2,8,16,17. The apparently low incidence of neurological 
signs (10.9%) is likely to be attributable in part to the effect of 
protocol-specified lumbar punctures on intracranial pressure.
Of note, signs of systemic disease such as conjunctival pallor 
(6.9%) and scleral icterus (2.9%) were particularly incident in 
our population. Anaemia is a common feature of advanced HIV 
disease and a side-effect of amphotericin B-based induction 
therapy, with increased mortality in patients with anaemia at 
baseline18. Hepatotoxicity is less common, but also well-described 
for both amphotericin B and fluconazole, as well as several 
commonly-used antiretroviral (ARV) drugs such as nevirapine 
and efavirenz. Jaundice may signal concomitant infection with 
chronic hepatitis C virus (HCV) or hepatitis B virus (HBV), as 
well as other opportunistic infections such as cytomegalovirus 
(CMV) and tuberculosis (TB). Simple ophthalmic examination 
can provide a mechanism for identifying these potentially 
complicating issues - both prior to and during anti-fungal 
treatment - and prompt further investigation.
Our data afford several advantages compared to previous case 
series. Firstly, the size of our study population (N=696) is 
considerably larger than those previously examined, allowing for 
a more comprehensive description of signs and symptoms and 
their relative incidence. Secondly, we assessed patients regularly 
across a range of time-points. Systematic screening at baseline 
allowed for identification of early ophthalmic signs, with 
prolonged (18-week) follow-up ensuring late manifesta-
tions were also captured. Finally, the simplicity of clinical 
examination allowed a wide range of presentation severities to be 
assessed, in contrast to previous studies limited to co-operative 
patients able to consent to comprehensive ophthalmological 
assessments2.
However, we recognise several limitations to our study. Firstly, 
although visual disturbances were systematically screened 
for, due to the nested nature of the study formal visual acuity 
testing was not performed, and therefore it is likely that we 
underestimated the proportion of patients with objective visual 
disturbance. Secondly, neither slit lamp examination nor indirect 
ophthalmoscopy was performed and therefore we are unable to 
comprehensively report on the prevalence of asymptomatic ante-
rior chamber or retinal pathology in our cohort. Thirdly, in most 
cases, no attempt was made to establish aetiology of reported 
visual disturbance. The use of dilated indirect ophthalmoscopy 
in conjunction with intracranial pressure measurement and 
imaging, would have aided in dividing ocular from neurological 
pathology. Mechanisms for visual loss have been discussed 
elsewhere2,19. In addition, we did not extract data regarding 
co-morbidities or medications with ophthalmic consequences, 
such as diabetes mellitus or ethambutol. Finally, our study was 
underpowered to detect an association between visual distur-
bance, cryptococcal disease severity and outcome.
Currently, limited published data exist describing ophthalmic 
features observed in HIV-associated cryptococcal cohorts. 
Prospective study – including routine slit lamp and indirect 
ophthalmoscopic examination - is urgently required into the 
correlation of reported visual disturbance with objective signs, in 
order to further clarify the underlying mechanisms and to guide 
effective diagnosis, follow-up and management.
Consent
Ugandan (MREC 429) and Minnesota (1304M31361) Institu-
tional Review Boards approved the ASTRO-CM trial protocol. 
All participants (or a surrogate, should the former demonstrate 
altered mental status or otherwise lack capacity) provided written 
informed consent.
Data availability
The database contains individual level data and as such is not 
available through an open-access data repository. The database 
is stored on a secure server at University of Minnesota. 
Researchers interested in accessing the data can contact the 
corresponding author (RRA; rachelatherton@doctors.org.uk), 
the last author (DRB; boulw001@umn.edu) or the Division of 
Biostatistics at the University of Minnesota (sph-ask@umn.edu). 
Data access will be granted to active researchers in the field 
with the agreement of the authors.
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